Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Strom, O
2558  Ergebnisse:
Personensuche X
?
1

Cost-effectiveness of romosozumab for the treatment of post..:

Söreskog, E. ; Lindberg, I. ; Kanis, J.A....
Osteoporosis International.  32 (2021)  3 - p. 585-594 , 2021
Link: https://doi.org/10.1007/..
 
?
2

A novel economic framework to assess the cost-effectiveness..:

Söreskog, E. ; Borgström, F. ; Lindberg, I....
Osteoporosis International.  32 (2021)  7 - p. 1301-1311 , 2021
Link: https://doi.org/10.1007/..
 
?
3

Real-world effectiveness of osteoporosis treatment in the o..:

Ström, O. ; Lauppe, R. ; Ljunggren, Ö....
Osteoporosis International.  31 (2020)  8 - p. 1525-1533 , 2020
Link: https://doi.org/10.1007/..
 
?
4

PUK6 A COST-EFFECTIVENESS MODEL FOR SECONDARY HYPERPARATHYR..:

Lilja, M. ; Lauppe, R. ; Intorcia, M....
Value in Health.  22 (2019)  - p. S913-S914 , 2019
Link: https://doi.org/10.1016/..
 
?
5

Risk of imminent fracture following a previous fracture in ..:

Banefelt, J. ; Åkesson, K.E. ; Spångéus, A....
Osteoporosis International.  30 (2019)  3 - p. 601-609 , 2019
Link: https://doi.org/10.1007/..
 
?
6

PMS43 - AN ECONOMIC VALUE FRAMEWORK TO ASSESS THE COST EFFE..:

Jonsson, E. ; Borgström, F. ; Ström, O....
Value in Health.  21 (2018)  - p. S295 , 2018
Link: https://doi.org/10.1016/..
 
?
7

Risk of Major Osteoporotic Fracture (Hip, Vertebral, Radius..:

Jonsson, E ; Ström, O ; Spångéus, A...
Value in Health.  20 (2017)  9 - p. A528 , 2017
Link: https://doi.org/10.1016/..
 
?
8

Quality of life for up to 18 months after low-energy hip, v..:

Svedbom, A. ; Borgstöm, F. ; Hernlund, E....
Osteoporosis International.  29 (2017)  3 - p. 557-566 , 2017
Link: https://doi.org/10.1007/..
 
?
9

Cost Effectiveness Evaluation of Fracture Liaison Services ..:

Jonsson, E ; Borgström, F ; Ström, O
Value in Health.  19 (2016)  7 - p. A612 , 2016
Link: https://doi.org/10.1016/..
 
?
10

The Economic Burden of Hepatitis C In France And Romania:

Ortsäter, G ; Ström, O ; Kautz, A
Value in Health.  19 (2016)  7 - p. A582 , 2016
Link: https://doi.org/10.1016/..
 
?
11

Cardiovascular risk factors and TIA characteristics in 19,8..:

Ström, J. O. ; Tavosian, A. ; Appelros, P.
Acta Neurologica Scandinavica.  134 (2016)  6 - p. 427-433 , 2016
Link: https://doi.org/10.1111/..
 
?
12

Persistence with denosumab and persistence with oral bispho..:

Karlsson, L. ; Lundkvist, J. ; Psachoulia, E...
Osteoporosis International.  26 (2015)  10 - p. 2401-2411 , 2015
Link: https://doi.org/10.1007/..
 
?
13

Systematic Review and Meta-Analysis of Persistence With Den..:

Jonsson, E. ; Cheng, L.I. ; Ström, O...
Value in Health.  17 (2014)  7 - p. A383-A384 , 2014
Link: https://doi.org/10.1016/..
 
?
14

Residual effect after oral bisphosphonate treatment and hea..:

Ström, O. ; Landfeldt, E. ; Garellick, G.
Osteoporosis International.  26 (2014)  1 - p. 315-325 , 2014
Link: https://doi.org/10.1007/..
 
?
15

Treatment Persistence in Swedish Women Initiating Denosumab..:

Karlsson, L. ; Lundkvist, J. ; Intorcia, M...
Value in Health.  16 (2013)  7 - p. A567 , 2013
Link: https://doi.org/10.1016/..
 
1-15